Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
July 16th, 2018
Tumor-seeking therapeutic mesenchymal stem cells (MSCs) show promise as a treatment for invasive glioblastoma. Optimal transplantation involves delivery of MSCs into the tumor resection cavity on scaffolds. Here, preclinical techniques to study MSC treatment of glioblastoma are provided including: image-guided tumor resection; implantation of MSC-seeded scaffolds; and postoperative therapy tracking.
Overview
This procedure focuses on the surgical resection of brain cancer in mice, followed by the implantation of a scaffold seeded with tumor-homing therapeutic mesenchymal stem cells (MSCs). It aims to investigate the effects of surgical resection on cell implantation and the efficacy of therapeutic agents in treating postsurgical brain cancer.
Key Study Components
Area of Science
- Neuro-oncology
- Cell therapy
- Stem cell research
Background
- Invasive glioblastoma is a challenging brain cancer.
- MSCs have potential as a treatment by targeting tumors.
- Scaffold-based delivery systems can enhance therapeutic outcomes.
- Studying these methods in mice can provide insights applicable to human treatments.
Purpose of Study
- To evaluate how surgical resection impacts cell implantation.
- To assess the effectiveness of new therapeutic agents post-surgery.
- To explore the influence of scaffold systems on treatment outcomes.
Methods Used
- Surgical resection of brain tumors in mice.
- Implantation of MSC-seeded scaffolds into resection cavities.
- Tracking postoperative therapy and outcomes.
- Preparation of scaffolds 48 hours prior to implantation.
Main Results
- Insights into the interaction between surgical techniques and cell therapy.
- Evaluation of the effectiveness of MSCs in a controlled environment.
- Demonstration of scaffold-based delivery systems' impact on therapy.
- Potential applications for other therapeutic interventions.
Conclusions
- This method closely mimics clinical care for brain cancer.
- It provides a framework for studying various therapeutic approaches.
- Further research can enhance understanding of stem cell therapies.
Frequently Asked Questions
Executive Industry Relevance
Image-guided resection combined with intracranial implantation of therapeutic stem cell-seeded scaffolds enables rigorous preclinical modeling of glioblastoma interventions. This approach addresses the translational gap in evaluating cell-based therapies and scaffold delivery systems under clinically relevant surgical conditions. The protocol supports predictive confidence for therapeutic persistence, tumor targeting, and intervention efficacy in neuro-oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of tumor microenvironment response to cell-based therapies post-resection.
- Supports functional validation of engineered MSCs for tumoricidal activity in vivo.
- Facilitates mechanistic de-risking of scaffold-mediated delivery platforms.
- Provides a model for evaluating persistence and localization of therapeutic cells.
Screening & Assay Development
- Establishes a reproducible system for quantitative tracking of therapeutic and tumor cells via fluorescence and luminescence.
- Standardizes scaffold preparation and cell seeding for downstream comparative studies.
- Enables assessment of intervention scalability and readiness for compound or biologic screening.
- Supports assay development for evaluating cell retention and therapeutic efficacy post-implantation.
Translational & Preclinical Research
- Aligns preclinical modeling with clinical surgical workflows for glioblastoma.
- Enables evaluation of translational biomarkers such as cell persistence and tumor recurrence.
- Supports risk-adjusted advancement of cell-based and scaffold-enabled therapies.
- Facilitates continuity from discovery through preclinical validation in neuro-oncology.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical validation, supporting lead identification and mechanistic de-risking for cell-based glioblastoma therapies.
- Discovery Biology: Provides a platform for hypothesis testing on therapeutic cell retention and tumor targeting post-resection.
- Screening: Delivers quantitative outputs for cell localization and tumor burden using dual fluorescent/luminescent markers.
- Analytics: Enables statistical comparison of intervention groups based on cell persistence and tumor recurrence metrics.
- Translational Research: Bridges preclinical findings to clinical surgical standards, informing biomarker alignment and therapeutic persistence.
- Enterprise Reuse: Adaptable for evaluating diverse interventions including nanoparticles, small molecules, and oncolytic viruses in the same surgical context.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in cell therapy efficacy and scaffold delivery mechanisms.
- Operational Value: Standardizes preclinical workflows for reproducibility and cross-study comparability.
- Strategic Value: Informs go/no-go decisions for advancing cell-based and scaffold-enabled therapies.
- Portfolio Impact: Supports risk-adjusted prioritization of neuro-oncology assets based on mechanistic and translational data.
Implementation Considerations
- Requires expertise in stereotaxic surgery and preclinical neuro-oncology models.
- Demands access to fluorescence/luminescence imaging and cell engineering infrastructure.
- Necessitates cross-team standardization of scaffold preparation and cell seeding protocols.
- Adaptable to various therapeutic modalities and engineered cell types.
- Intrinsic variability in surgical resection extent must be managed for data consistency.
Biopharma FAQs
Chapters in this video
0:04
Title
1:06
Cell Culture and Scaffold Preparation
4:27
Fluorescence-Guided Resection and Scaffold Implantation
7:35
Results: Representative Images of Fluorescent Cancer Cells and MSCs Seeded on Resorbable Electrospun Nanofibrous Poly(Lactic Acid)
8:36
Conclusion
